Coagulation and platelet activation pathways. A review of the key components and the way in which these can be...

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Acute coronary syndromes (ACS) involve thrombotic obstruction of diseased arteries, primarily due to platelet and fibrin aggregation.
• Historically, antithrombotic treatment options for ACS were limited to aspirin, heparin, and dicumarol.
• Advances in understanding the pathophysiology of ACS have led to a significant expansion of available antithrombotic therapies.

Purpose of the Study:

• To review the physiological mechanisms of platelet activation and coagulation cascade.
• To discuss the therapeutic manipulation of these pathways in the context of acute coronary syndromes.
• To provide an overview of the current landscape of antithrombotic drug development and application.

Main Methods:

• Literature review of physiological processes involved in thrombosis.
• Analysis of the mechanisms of action for various antithrombotic agents.
• Synthesis of information on therapeutic strategies for managing acute coronary syndromes.

Main Results:

• Detailed explanation of platelet activation pathways, including receptor-ligand interactions and signaling cascades.
• Comprehensive overview of the coagulation cascade, highlighting key enzymes and cofactors.
• Discussion of novel antithrombotic drugs targeting specific components of platelet aggregation and fibrin formation.

Conclusions:

• A deeper understanding of thrombosis has revolutionized ACS treatment.
• The expanded range of antithrombotic drugs offers more targeted and effective therapeutic options.
• Continued research into thrombotic mechanisms promises further advancements in ACS management.